Martin Evans

Sir Martin John Evans (1 January 1941 – Present) is a British developmental biologist renowned for his pioneering work on embryonic stem cells and genetics. His groundbreaking research has significantly contributed to the fields of medicine and genetics, earning him the Nobel Prize in Physiology or Medicine in 2007, which he shared with Mario Capecchi and Oliver Smithies. Their work laid the foundation for gene targeting in mice, a technique that has become crucial in understanding gene function and has led to the development of genetically modified organisms (GMOs) for research.
Early Life and Education[edit]
Martin Evans was born in Stroud, Gloucestershire, England. He pursued his education at the University of Cambridge, where he initially studied biochemistry at Christ's College. He later obtained his PhD from the University of London, focusing on the cultivation and differentiation of mouse embryonic cells, which would become the cornerstone of his future research endeavors.
Career and Research[edit]
Evans began his career in academia, holding positions at various prestigious institutions. His early work involved exploring the potential of mouse embryonic cells, which led him to the discovery of embryonic stem cells in mice. This discovery was monumental, as it opened up new avenues for research into genetic manipulation and disease modeling in mammals.
In 1981, Evans, along with his colleagues, successfully isolated and cultured embryonic stem cells from mouse embryos, a feat that had not been achieved before. This breakthrough allowed for the manipulation of mouse genomes in a controlled environment, paving the way for the development of gene targeting techniques. These techniques enabled scientists to introduce specific gene modifications into mice, thereby creating models for studying human diseases, understanding gene function, and developing new therapeutic strategies.
Throughout his career, Evans has received numerous accolades for his contributions to science, including the Knighthood in 2004 for services to medical science and the Nobel Prize in 2007. His work has had a profound impact on genetic research, offering insights into the genetic basis of diseases and the potential for gene therapy.
Legacy and Impact[edit]
Sir Martin Evans' contributions to the field of developmental biology and genetics have been transformative. His work on embryonic stem cells and gene targeting has revolutionized the way researchers study genetic diseases and develop treatments. The techniques he helped develop are now standard tools in biomedical research, enabling the creation of genetically modified animal models that mimic human diseases more accurately than ever before.
His research has not only advanced our understanding of genetics and developmental biology but has also had practical implications in the development of new therapies for a range of diseases. The ability to manipulate genes in mice has been instrumental in the discovery of new drugs and treatments, making Evans' work foundational in the field of modern medicine and biotechnology.
Selected Publications[edit]
- Evans, M.J., & Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature.
- Other significant publications spanning his career, detailing the development and refinement of embryonic stem cell techniques and gene targeting.
Awards and Honors[edit]
- Nobel Prize in Physiology or Medicine (2007)
- Knighthood for services to medical science (2004)
- Various other awards and honors recognizing his contributions to science and medicine.
See Also[edit]
- Embryonic stem cells
- Gene targeting
- Genetically modified organisms
- Nobel Prize in Physiology or Medicine
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian